Lewis JD - Search Results

1

Comparative Effectiveness of Nutritional and Biological Therapy in North American Children with Active Crohn's Disease.

Lee D, Baldassano RN, Otley AR, Albenberg L, Griffiths AM, Compher C, Chen EZ, Li H, Gilroy E, Nessel L, Grant A, Chehoud C, Bushman FD, Wu GD, Lewis JD. Lee D, et al. Among authors: lewis jd. Inflamm Bowel Dis. 2015 Aug;21(8):1786-93. doi: 10.1097/MIB.0000000000000426. Inflamm Bowel Dis. 2015. PMID: 25970545

2

How safe is immunomodulator therapy?

Lewis JD. Lewis JD. Inflamm Bowel Dis. 2001 May;7(2):178-9. doi: 10.1097/00054725-200105000-00019. Inflamm Bowel Dis. 2001. PMID: 11383594 No abstract available.

3

An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis.

Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD. Lewis JD, et al. Am J Gastroenterol. 2001 Dec;96(12):3323-8. doi: 10.1111/j.1572-0241.2001.05333.x. Am J Gastroenterol. 2001. PMID: 11774944

4

Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.

Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR. Su C, et al. Among authors: lewis jd. Am J Gastroenterol. 2002 Oct;97(10):2577-84. doi: 10.1111/j.1572-0241.2002.06026.x. Am J Gastroenterol. 2002. PMID: 12385442

5

Patterns of complementary and alternative medicine use in a population of pediatric patients with inflammatory bowel disease.

Markowitz JE, Mamula P, delRosario JF, Baldassano RN, Lewis JD, Jawad AF, Culton K, Strom BL. Markowitz JE, et al. Among authors: lewis jd. Inflamm Bowel Dis. 2004 Sep;10(5):599-605. doi: 10.1097/00054725-200409000-00015. Inflamm Bowel Dis. 2004. PMID: 15472521

6

Predictors of recall of over-the-counter and prescription non-steroidal anti-inflammatory drug exposure.

Lewis JD, Strom BL, Kimmel SE, Farrar J, Metz DC, Brensinger C, Nessel L, Localio AR. Lewis JD, et al. Pharmacoepidemiol Drug Saf. 2006 Jan;15(1):39-45. doi: 10.1002/pds.1134. Pharmacoepidemiol Drug Saf. 2006. PMID: 16136614

7

Design issues and outcomes in IBD clinical trials.

Sands BE, Abreu MT, Ferry GD, Griffiths AM, Hanauer SB, Isaacs KL, Lewis JD, Sandborn WJ, Steinhart AH. Sands BE, et al. Among authors: lewis jd. Inflamm Bowel Dis. 2005 Nov;11 Suppl 1:S22-8. doi: 10.1097/01.mib.0000184849.38816.39. Inflamm Bowel Dis. 2005. PMID: 16254479 Review.

8

Immunomodulators and the need for surgery in Crohn's disease: insufficient evidence to convict.

Lewis JD. Lewis JD. Inflamm Bowel Dis. 2005 Dec;11(12):1120-2. doi: 10.1097/01.mib.0000186493.50815.d9. Inflamm Bowel Dis. 2005. PMID: 16306776 No abstract available.

9

Risk of serious upper gastrointestinal toxicity with over-the-counter nonaspirin nonsteroidal anti-inflammatory drugs.

Lewis JD, Kimmel SE, Localio AR, Metz DC, Farrar JT, Nessel L, Brensinger C, McGibney K, Strom BL. Lewis JD, et al. Gastroenterology. 2005 Dec;129(6):1865-74. doi: 10.1053/j.gastro.2005.08.051. Gastroenterology. 2005. PMID: 16344055

10

Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease.

Morales A, Salguti S, Miao CL, Lewis JD. Morales A, et al. Among authors: lewis jd. Inflamm Bowel Dis. 2007 Apr;13(4):380-5. doi: 10.1002/ibd.20028. Inflamm Bowel Dis. 2007. PMID: 17206711

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,177 results

Search Page